Synlogic Stock (NASDAQ:SYBX)
Previous Close
$1.42
52W Range
$0.23 - $5.71
50D Avg
$1.53
200D Avg
$2.12
Market Cap
$16.96M
Avg Vol (3M)
$13.68K
Beta
0.84
Div Yield
-
SYBX Company Profile
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
SYBX Performance
Peer Comparison
Ticker | Company |
---|---|
FDMT | 4D Molecular Therapeutics, Inc. |
FRTX | Fresh Tracks Therapeutics, Inc. |
MNPR | Monopar Therapeutics Inc. |
ACIU | AC Immune SA |
EWTX | Edgewise Therapeutics, Inc. |
SABS | SAB Biotherapeutics, Inc. |
STOK | Stoke Therapeutics, Inc. |
ERAS | Erasca, Inc. |
GBIO | Generation Bio Co. |
SRZN | Surrozen, Inc. |
KRON | Kronos Bio, Inc. |
PASG | Passage Bio, Inc. |
VCNX | Vaccinex, Inc. |
ANTX | AN2 Therapeutics, Inc. |
CCCC | C4 Therapeutics, Inc. |
EFTR | eFFECTOR Therapeutics, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
PCSA | Processa Pharmaceuticals, Inc. |
THRD | Third Harmonic Bio, Inc. |
TARA | Protara Therapeutics, Inc. |
GRTX | Galera Therapeutics, Inc. |